Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep‐Vein Thrombosis as First‐Line Therapy (AMPLIFY) Trial

Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep‐Vein Thrombosis as First‐Line Therapy (AMPLIFY) Trial

Background In the Apixaban for the Initial Management of Pulmonary Embolism and Deep‐Vein Thrombosis as First‐Line Therapy (AMPLIFY) trial, apixaban was noninferior to enoxaparin/warfarin in preventing recurrent symptomatic venous thromboembolism (VTE) or venous thromboembolism–related death, with s...

Full description

Bibliographic Details
Main Authors: Xianchen Liu, Margot Johnson, Jack Mardekian, Hemant Phatak, John Thompson, Alexander T. Cohen
Format: Article
Language:English
Published: Wiley 2015-12-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
anticoagulants
hemorrhage
mortality
prevention
thrombosis
Online Access:https://doi.org/10.1161/JAHA.115.002340

Internet

https://doi.org/10.1161/JAHA.115.002340

Similar Items